Reference : Prospective pilot evaluation of the efficacy and safety of topical ingenol mebutate g...
Scientific journals : Article
Human health sciences : Dermatology
http://hdl.handle.net/2268/229916
Prospective pilot evaluation of the efficacy and safety of topical ingenol mebutate gel for localized patch/plaque stage mycosis fungoides
English
LEBAS, Eglantine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie >]
CASTRONOVO, Charlotte [Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie >]
ARRESE ESTRADA, Jorge [Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire cytopatho, couche cornée, ongles & trichologie >]
Libon, Florence [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
TASSOUDJI, Nazli [Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie >]
SEIDEL, Laurence mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME) >]
Nikkels, Arjen mailto [Université de Liège - ULiège > Département des sciences cliniques > Dermatologie >]
2017
Open Dermatology Journal
Bentham Science Publishers B.V.
11
98-107
Yes (verified by ORBi)
1874-3722
[en] Alternative topical treatment option ; Ingenol mebutate ; Mycosis fungoides ; PCNKTCL ; CD3 antigen ; CD4 antigen ; CD45RO antigen ; CD8 antigen ; T lymphocyte receptor ; Article ; Composite Assessment of Index Lesion Severity
[en] Background: Mycosis Fungoides (MF) is the most frequent type of the primary cutaneous NK/T-cell lymphomas. Ingenol mebutate (IM) displays in vitro pro-apoptotic properties on neoplastic lymphocytes. Objectives: To evaluate the efficacy and safety of IM gel as topical treatment for MF. Materials and Methods: Ten male patients with longstanding classic type MF (n=9) and follicular MF (FMF; n=1), T2bN0M0B0, stage Ib, resistant to systemic methotrexate or acitretin therapies for at least 3 months, were included in this pilot study. In these patients, 11 target patch/plaque stage lesions with an area ≤ 25 cm2 were selected for IM therapy (0,05%, 2 weekly applications). The primary endpoint was the improvement of the CAILS scores. Biopsies were performed before and after treatment from 10 target lesions. Relapse rates were evaluated at 6 months. Results: The mean CAILS score of treated target lesions was reduced by 58.2%. The mean erythema, scaling and plaque elevation scores were improved by 73.6%, 93.9% and 97.9% (p<0.0001), respectively, while the lesion size remained unchanged (p=0.34). A complete or partial clearance of histological and immunohistochemical features was observed in 6/10 (60%) and 4/10 (40%) of the MF or FMF target lesions, respectively. Monoclonal TCR rearrangement was evidenced in 100% (7/7) of the patients and in 3/7 (43%) after treatment. The relapse rate at 6 months was 18%. All the patients experienced burning sensations, oozing and crusting. Conclusion: IM gel warrants further investigation and development as a potential topical treatment for localized patch/plaque stage MF and FMF. © 2017 Lebas et al.
http://hdl.handle.net/2268/229916
10.2174/1874372201711010098

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
TODJ-11-98.pdfPublisher postprint1.32 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.